The transcription factor Cdx1 regulates intestine-specific gene expression and enterocyte differentiation. It has been hypothesized to play a role in regulating intestinal cell proliferation; however, the mechanism for this effect remains elusive. In a prior study, we demonstrated that Cdx1 expression reduced the proliferation of a nontransformed intestinal cell line. This study tests the hypothesis that Cdx1 expression inhibits colon cancer cell proliferation by reducing cyclin D1 gene expression. Cdx1 expression markedly reduced cancer cell proliferation and DNA synthesis and induced an accumulation of cells in G0/G1. A transcriptionally inactive Cdx1 mutant could not elicit this effect, suggesting that it required Cdx1 transcriptional activity. Cdx1 expression increased the hypophosphorylation of the retinoblastoma (pRb) and p130 proteins. Reductions in G1 cyclin-dependant kinase (cdk) activity accompanied this effect. Cyclin D1 mRNA and protein levels were diminished by Cdx1 expression. Restoration of cyclin D1 expression reversed the G0/G1 block and induced pRb hyperphosphorylation. Lastly, Cdx1 expression did not alter cyclin D1 mRNA stability but did reduce cyclin D1 promoter activity, suggesting that Cdx1 acts to diminish cyclin D1 gene transcription. We conclude that Cdx1 reduces the proliferation of human colon cancer cells by reducing cyclin D1 gene transcription.
Introduction
Colon cancer is the second leading cause of cancer death in the US, responsible for nearly 60,000 deaths each year. A large body of evidence supports the hypothesis that most human colon cancers arise from adenomas. Adenomas arise when somatic mutations are acquired, which disrupt the highly ordered process of epithelial renewal that occurs continuously throughout the small intestine and colon (Chung, 2000; Lynch and Hoops, 2002) .
Normally, surface cells are lost to the intestinal lumen due to programmed cell death (apoptosis) or mechanical exfoliation and must be replaced. Renewal depends on a regulated process of proliferation of stem cells and differentiation of daughter cells. Proliferation occurs within a zone or compartment of the crypts of the small intestine and colon. Daughter cells continue proliferating as they migrate up along the crypt-villus axis. At the upper third of the crypt, proliferation ceases and the cells undergo a rapid maturation. The transition from rapidly proliferating cells to nondividing, mature enterocytes is swift. Some of the mechanisms regulating these events have been identified, including the Wnt and Notch signaling pathways (Korinek et al., 1998; Jensen et al., 2000) and certain transcription factors such as the Drosophila Caudal-related factors Cdx1 and Cdx2.
The homeodomain proteins Cdx1 and Cdx2 are wellrecognized regulators of intestine-specific gene expression and enterocyte differentiation (Suh et al., 1994; Suh and Traber, 1996; Taylor et al., 1997; Freund et al., 1998; Soubeyran et al., 1999) . Cdx1 and Cdx2 are important transcriptional activators, promoting the intestine-specific expression of a number of genes including sucrase isomaltase, colon carbonic anhydrase 1, and intestinal phospholipase A/lyso-phospholipase (IPAL) (Suh et al., 1994; Taylor et al., 1997; Drummond et al., 1998) . Cdx1 and Cdx2 also promote differentiation of intestinal cells (Suh and Traber, 1996; Soubeyran et al., 1999) . Additionally, observations utilizing a variety of experimental methods suggest that these factors can regulate intestinal cell proliferation. There is consensus among investigators that Cdx2 expression reduces intestinal epithelial proliferation (Suh and Traber, 1996; Freund et al., 1998) . However, the findings with respect to Cdx1's role in control of proliferation have been conflicted.
Cdx1 is expressed in the intestinal crypts and Wnt/bcatenin signaling is required for Cdx1 expression (Subramanian et al., 1998; Lickert et al., 2000) . These observations seem to support the premise that Cdx1 promotes proliferation. However, Cdx2, which reduces proliferation, is also expressed in intestinal crypts (Rings et al., 2001) . Additionally, dysregulation of the Wnt/bcatenin signaling pathway is nearly universally present in human colon cancers (Chung, 2000; Lynch and Hoops, 2002 ); yet Cdx1 expression is preferentially silenced with the progression to colon cancer in humans Suh et al., 2002) . Together, these findings cast doubt on the premise that Cdx1 promotes proliferation.
In vitro studies using cell culture models have yielded conflicting observations as well. Cdx1 expression in 3T3 cells results in soft-agar growth and tumor formation in one study (Maulbecker and Gruss, 1993) but not in another study (Lynch et al., 2000) . Stable constitutive Cdx1 expression in human colon cancer cell lines has been reported to have no effect on proliferation (Mallo et al., 1998) , or reduce tumor growth synergistically with Cdx2 in vivo (Mallo et al., 1998) . Antisense Cdx1 expression reduced proliferation of human colon cancer CaCo2 cells (Lorentz et al., 1997) . Lastly, Cdx1 expression in rat IEC6 cells increased cell proliferation in one study (Soubeyran et al., 1999) but not in another study (Lynch et al., 2000) . One factor complicating the interpretation of these studies is the use of pooled cells constitutively expressing CDX1, which were selected for growth in spite of CDX1 gene expression. Cells with reduced proliferation would therefore be overgrown and not detected. It is thus not a sensitive method for detecting antiproliferative effects.
In our present study with human colon cancer cells, we analyse in detail the molecular basis of Cdx1-mediated inhibition of proliferation. Transient expression of Cdx1 in human colon cancer DLD1 and HCT116 cells resulted in a marked reduction of proliferation, with an accumulation of cells in the G0/ G1 phase of the cell cycle. Importantly, this effect was specific, as an N-terminally truncated Cdx1 protein was unable to elicit this effect. Similar to our findings in IEC6 cells, the retinoblastoma protein (pRb) and the related p130 protein were predominantly hypophosphorylated. Unlike our prior studies, this was associated primarily with reductions in G1 cdk6 and cdk2 kinase activities. Cyclin D1 mRNA and protein levels were diminished as before, but we now confirm that this decrease is critical for the Cdx1 antiproliferative effect, as restoration of cyclin D1 activity reversed the Cdx1-mediated G0/G1 arrest. Additionally, we demonstrate that Cdx1 expression does not alter cyclin D1 mRNA stability, but does reduce transcriptional activity from a human cyclin D1 promoter. Taken together, we conclude that Cdx1 expression in human colon cancer cells reduces proliferation by decreasing cyclin D1 gene transcription. These findings suggest that Cdx1 may play a role in coordinating cell-cycle exit with the induction of differentiation that occurs as cells ascend from the intestinal and colonic crypts, and loss of CDX1 expression in human colon cancers may contribute to their increased proliferation.
Materials and methods

Production and expression of adenovirus vectors and adenoviral infections
A mouse Cdx1 cDNA was subcloned into the basic adenoviral transfer vector (pAdCMVlink) and used to produce the expression vector Adeno-CDX1 as described previously (Lynch et al., 2000) . pAdCMVlink without a cDNA insert was used to generate the control Adeno-NULL vector. Infectious titers were determined by an adenoviral plaque assay. The human cyclin D1 adenovirus (Ad-cyclin D1; Albrecht and Hansen, 1999) was provided by J Albrecht (University of Minnesota). It was expanded and titered in the same manner as the pAd-Cdx1 and pAd-Null viruses.
Adenovirus infections were performed as described (Lynch et al., 2000) . DLD and HCT116 cells were initially plated sparsely, 14.3 Â 10 4 per 100 mm plate or 5 Â 10 3 /well in a 24-well culture dish. The adenovirus concentration yielding 490% of cells expressing Cdx1 was determined experimentally for each cell line using the antibody CPSP (1 : 200) , a rabbit anti-Cdx1 antibody. An adenoviral concentration of 1.68 Â 10 6 infectious particles/ml was determined to be optimal for DLD1 cells, and 3.75 Â 10 6 infectious particles/ml for HCT116 cells, when cells were initially plated at sparse concentrations. These concentrations were used in the subsequent experiments. Based on these values, a calculation of the multiplicity of infection (MOI) would yield 67 for DLD1 cells, and 150 for HCT116 cells. These MOI's are artificially inflated by the relatively low cell density we used in order to avoid confounding contributions from contact inhibition.
At 48 h postadenoviral infection, the cells were processed for the various end points. For cell counts, the cells were trypsinized at several points postinfection, pelleted by centrifugation, resuspended in PBS, and counted on a hemecytometer. Plates of DLD1 cells (100 mm) were infected and whole-cell protein, nuclear proteins, or total RNA were isolated at 48 h. EMSA for Cdx DNA-binding activity and immunoblots for Cdx1 and Cdx2 protein were performed exactly as described (Lynch et al., 2000) .
Cell culture and transfections
DLD1 and HCT116 cells were obtained from the ATCC maintained under standard conditions. Cdx1 truncation constructs were synthesized by PCR using oligos to amplify Cdx1 truncations from a murine cDNA template. These amplified products were sequenced to confirm fidelity of the amplification and subcloned into the mammalian expression vector pRC/CMV (Promega). N-terminus deletion primers were: 5 0 -TTGGATCCACCATGAAGACCCGAAC-CAAGG-3 0 and 5 0 -TTTGATCACTAGGGTAGAAACTCC-TCCTT-3 0 . The C-terminus deletion primers were: 5 0 -TTGG-ATCCACCATGTACGTGGGCTATGTGC-3 0 and 5 0 -TTT-GATCACTACTTCTTGTTTACTTTGCGC-3 0 . pRC/CMVCdx1 was constructed as described .
HCT116 cells were transfected using FuGENE6 (Roche). Luciferase assays were carried out using the Dual Luciferase Assay Kit and the pRL-CMV vector (both by Promega) as transfection control. Sparsely plated HCT116 cells were transfected with pMACSK k .II (Miltenyi) and the appropriate pRC/CMV expression vectors in a ratio of 1 : 3. At 48 h, cells were washed, trypsinized, and dead cells removed using the Dead Cell Removal Kit (Miltenyi), followed by a single enrichment for H-2K k -expressing cells using the MACSelect K k .II kit (Miltenyi). Isolated cells were fixed in PBS/70% EtOH at À201C overnight. On the following day, cells were washed in PBS, stained with propidium iodide (50 mg/ml) and RNAse A (360 mg/ml) for 30 min at 371C, then with just propidium iodide (50 mg/ml) in PBS for at least 1 h at 41C. DNA content was quantified using a FACSCAN (Becton Dickson). DLD1 cells were transfected by electroporation exactly as described (Krasinski et al., 2001 ) using a Pulse Controller II (Bio-Rad), and 6 mg of pRC expression vectors, 1 mg of GFP-F (Clontech), and 28 mg of Bluescript II SK þ (Stratagene) as carrier. Media were changed at 24 h, and at 48 h the cells were harvested and fixed as above in PBS/70% EtOH at À201C. The following day, the cells were washed and stained as above with propidium iodide. DNA content was quantified by flow cytometry, with gating on GFP þ DLD1 cells. A human cyclin D1promoter-luciferase reporter construct D1pro-1749 (PvuII) was provided by Dr Anil Rustgi (University of Pennsylvania).
BrdU and flow cytometry assays
BrdU incorporation was measured as before (Lynch et al., 2000) using the 5-bromo-2 0 -deoxyuridine Labeling and Detection Kit I (Boehringer Mannheim). DLD1 cells were infected and cultured as described, with BrdU labeling being performed over 1 h. The percentages of BrdU þ cells were transformed using the arcsine transformation prior to statistical analysis with ANOVA and Tukey tests. Some treated cells at 48 h were stained for Cdx1 (using polyclonal CPSP) along with BrdU, and then counterstained by DAPI. The cells were examined by fluorescent microscopy and images obtained using a Photometrix Coolsnap-CF Black and White CCD camera (Roeper Scientific) mounted on a Nikon E600 fluorescent microscope.
DNA content was measured using a rapid propidium iodidestaining method as described (Lynch et al., 2000) . DNA content quantitation was carried out using FACScan (Becton Dickson).
RNAse protection and RNA stability determinations
Total RNA was isolated using RNAeasy (QIAGEN) from several 100 mm plates of infected DLD1 cells. For the cyclin D1 mRNA stability studies, 10 mg/ml Actinomycin D (Sigma) was added to the cultures at 48 h postinfection and cultures continued for 4-24 h. Riboprobes for the human cyclin genes were synthesized using the Human Cell Cycle Regulator Template Set (hCYC-1, PharMingen) and T7 RNA polymerase, as described by the manufacturer. The probe set was hybridized to 5 mg of total RNA and then subject to RNAse T1 digestion using the buffers and conditions recommended by the RPA II kit (Ambion). The products were analysed on a 7 m urea/ 5% acrylamide sequencing gel, dried down and exposed to film and quantified by exposure to a phosphoimager screen (STORM 840, Molecular Dynamics). Total RNA (10 or 20 mg) was analysed by Northern blotting for c-Myc, cyclin D1, and 36B4 mRNA expression as described (Lynch et al., 2000) . Probes for human c-Myc cDNA (kindly provided by Gary Wu, University of Pennsylvania, USA), cyclin D1 (Hiroshi Nakagawa, University of Pennsylvania, USA), and ribosomal phosphoprotein 36B4 (Francois Boudreau, University of Pennsylvania, USA), were random-primed 32 P-labeled and used as a probe (Ambion).
Immunoblot analysis
Several 100 mm plates of DLD1 cells were infected and cultured. At 48 h, a whole-cell extract was prepared as described (Lynch et al., 2000) and the products analysed by SDS-PAGE electrophoresis and electroblotted. The following antibodies were used: pRb:G3-245 (Pharminigen); cyclin D1:06-137 (Upstate Biotechnology), SC-246 (Santa Cruz), and DCS-6 (BD Pharmingen); p130:SC-317; p107:SC-250; cyclin A:SC-751; cyclin B1:SC-245; cyclin D2:SC-452; cyclin D3:SC-182; cyclin E:SC-481; cdk2:SC-163; cdk4:SC-260; cdk6:SC-177; p15:SC-613; p16:SC-1661; p18:SC-865; p19:SC-1063; p21:SC-397; p27:SC-1641; p57:SC-1040; (Santa Cruz); actin:A-4700 (Sigma). Positive controls for p16, p21, and p27 were included to confirm antibody activity and specificity. After washing the membrane, the blot was incubated with the secondary antibody (antiRabbit/HRP (Amersham), antimouse/HRP or antigoat/HRP (Santa Cruz)); the blot was developed with the ECL-Plus Western blotting kit (Amersham).
Cyclin-dependent kinase activity analysis
Cdk4 and cdk6 kinase activity assays were carried out as described (Phelps and Xiong, 1997; Lynch et al., 2000) . Several 100 mm plates of DLD1 cells were infected and cultured and an immunoprecipitation (IP) protein extract prepared at 48 h. Cleared lysates were then subject to IP with 1 mg of either anticdk4 (sc-601, Santa Cruz) or anti-cdk6 (sc-177, Santa Cruz), or 1 mg of rabbit preimmune IgG (sc-2026, Santa-Cruz), and then kinase activity was determined as described (Lynch et al., 2000) .
Cdk2-associated kinase activity was measured in a similar fashion (Sheaff, 1997; Hu et al., 2001) . The same IP extracts used in the cdk4/6 assays were incubated with either 1 mg of anti-cdk2 (sc-163, Santa Cruz) or rabbit preimmune IgG, followed by incubation with prewashed Protein A beads and then several washes with IP and K2 kinase buffers (K2 kinase buffer: 25 mm HEPES (pH 7.5), 15 mm MgCl 2 , 0.5 mm DTT, 1 mm NaF, 0.1 mm Na 3 VO 4 , 100 mm PMSF, 2 mg/ml leupeptin, 2 mg/ml of aprotinin). To initiate the Cdk2 reaction, 10 ml of kinase buffer with 100 mm cold ATP, 5 mCi g-32 P-ATP, and 0.5 mg of histone H1 (Sigma H-4524) was then added to the pelleted beads, and the reaction incubated at 301C for 30 min with frequent agitation. The reaction was halted and products were analysed by SDS-PAGE.
Results
Inhibition of proliferation of human colon cancer cell lines by Cdx1 expression
CDX1 expression is diminished or lost in the progression from normal colonocyte to colon adenocarcinoma. To determine if this loss contributed to the increased proliferation characteristic of human colon cancer cells, we tested two human colon cancer cell lines for growth effects with the induction of Cdx1 expression: DLD1 and HCT 116. Neither of these cell lines expresses significant CDX1 protein and both express CDX2 but at different levels (data not shown). We utilized a Cdx1-adenoviral expression vector (Adeno-Cdx1) and confirmed the production of authentic Cdx1 protein in our cells. An adenovirus with an empty expression cassette (Adeno-Null) was used as a control. Extracts from Adeno-Cdx1, Adeno-Null, and control uninfected cells were compared by Western blot and EMSA (data not shown), and clearly demonstrated induction of a DNAbinding Cdx1 protein by the Adeno-Cdx1 vector.
We determined initially an optimal adenoviral infectious particle concentration for each cell type such that X90% of cells in culture are infected and expressing Cdx1 as determined by immunofluorescence (data not shown). In order to avoid confounding contributions from contact inhibition on our measures of proliferation, we carried out adenoviral infections at very low cell densities. Actual adenoviral concentrations ranged from 1.68 Â 10 6 (DLD1) to 3.75 Â 10 6 (HCT116) infectious adenoviral particles per ml of cell culture media. These levels were not cytotoxic. Using this optimal concentration, we tested for effects on cell accumulation after infection with either the AdenoCdx1 vector or our control adenovirus without the Cdx1-cDNA insert (Adeno-Null). Both cell lines responded to Cdx1 expression with a reduction in cell accumulation ( Figure 1a ). The effect became more apparent 3-4 days after infection with the AdenoCdx1 vector. We found that DLD1 cells had the most significant reduction in accumulation with Adeno-Cdx1 and were not significantly effected by the control Adeno-Null vector. For this reason, we focused the studies that followed on Cdx1 expression in DLD1 cells.
The rate of DNA synthesis was reduced by Cdx1 expression. BrdU incorporation into DNA was decreased twofold by 48 h after infection with the AdenoCdx1 virus (Figure 1b, c) . Moreover, the nuclei of Cdx1-expressing cells were not different from Adeno-Nulltreated and control DLD1 cells. There was no evidence for increased apoptotic cell death with these treatments (Figure 1b) . Thus, Cdx1 expression inhibited proliferation by reducing DNA synthesis in human DLD1 cells and not by increasing cell death.
Cdx1 expression in DLD1 cells induces a G0/G1 cell-cycle block
Inhibition of proliferation and DNA synthesis is typically associated with a cell-cycle arrest. To investigate this possibility, cells were infected as before, and DNA content analysed by propidium iodide staining and flow cytometry. We did not observe subdiploid peaks of DNA content in the cytometry profiles, further demonstrating that apoptosis was not occurring (data not shown). Adeno-Cdx1 virus infection induced a (Table 1) . Adeno-cdx1 treatment led to a 1.6-fold increase in the number of cells in the G0/G1 phase of the cell cycle. We found that Cdx1 expression reduced the S phase population by twofold, consistent with our results from the BrdU analysis. By contrast, Adeno-Null control treatment induced a modest reproducible reduction of cells in G0/G1. Thus, Cdx1 expression in DLD1 cells inhibits proliferation by blocking cell-cycle progression in G0/G1.
Cdx1 expression affects G1/S transition regulatory proteins
The retinoblastoma family of phosphoproteins (pRb, p107, and p130) are key regulators of the G1/S transition in eukaryotic cells. We next studied the expression of these proteins in DLD1 cells to better understand the Cdx1-mediated G0/G1 block. Hypophosphorylated forms of these proteins are associated with an inhibition of transcriptional events required for the G1/S transition (Sherr, 2000) . We consistently noted that faster migrating, hypophosphorylated pRb and p130 forms were induced by Cdx1 expression over many experiments (Figure 2a) . Total pRb and p130 protein levels were not quantified. p107 was not detected (data not shown).
The pRb phosphorylation state exquisitely regulated during G1 by the D and E cyclins, cyclin-dependent kinases (cdks), and cdk inhibitors (CDKI). We next examined these regulators for Cdx1-induced changes. Except for p57, expression levels of Cip/Kip (p21, p27) or Ink4 (p15, p16, p18, p19) cdk inhibitors were below the level of detection by Western blot (data not shown). , and D3 mRNA, as well as control L32 and GAPDH, were analysed in duplicate by RNAse protection using the RiboQuant multiprobe template. Protected probe bands were quantified by exposure to a phosphoimager screen (STORM 840, Molecular Dynamics). Results from two experiments were normalized to controls L32 and GAPDH, averaged, and expressed as percent of control levels graphically. Con: control uninfected cells; Null: Adeno-nullinfected cells; Cdx1: Adeno-Cdx1-treated cells Although p57 was detected, its levels were low and unaltered by Cdx1 expression (data not shown). Of the G1 cyclins, only cyclin D1 levels were markedly reduced by Cdx1 expression (Figure 2b ). Cyclin D3 levels were slightly decreased, cyclin D2 was not detected, and cyclin E was unaffected by Cdx1 (Figure 2b and data not shown). Cyclins A and B1 levels were both reduced, as would be expected for cells accumulating in G0/G1. Taken together, the Western blot data suggest that Cdx1 induces a G0/G1 accumulation by reducing pRb phosphorylation through a specific reduction in cyclin D1 protein levels rather than by induction of a cdk inhibitor. We next performed Northern blot and RNAse protection analysis on total RNA isolated from shaminfected, Adeno-null-infected, or Adeno-Cdx1-treated DLD1 cells for 48 h. By these techniques, Cdx1 expression reduced cyclin D1 mRNA levels to 33% of control levels (range 25-45%) (Figures 2c, d ). Cyclins A and B mRNA levels were reduced by about 50% from control levels (Figure 2c, d) . After normalization to controls L32 and GAPDH and averaging the results from several experiments, Cyclin D3 mRNA levels were only modestly diminished, decreased by 30%. In summary, Cdx1 expression reduced mRNA levels of cyclins A,B, D1, and D3, but the most profound effect was observed with cyclin D1 mRNA levels.
Time course analysis of cell-cycle arrest and reductions in cyclin D1 mRNA and protein levels
To better understand the relation between the Cdx1-induced G0/1 accumulation and falling cyclin D1 mRNA and protein levels, we performed a time course analysis. DLD1 cells were infected as before, and analysed for DNA content by flow cytometry at 12, 24, and 48 h post-adenoviral infection. There was no significant difference in the percentage of cells in G0/G1 in the two treatment groups during the first 24 h. However, by 48 h, we do see a large increase in the percentage of Cdx1-expressing DLD1 cells in G0/G1 (Figure 3a) . Additionally, while there was no difference in the %G0/G1 at 24 h, we did observe a small but reproducible reduction in the %S phase, with a reciprocal increase in the %G2/M phase of Cdx1-expressing cells at 24 h (data not shown). This agrees with the small reduction in BrdU incorporation noted at 24 h in the Adeno-Cdx1-treated cells (Figure 1) .
We then isolated both protein and RNA from AdenoCdx1-treated cells at the same time points and performed immunoblot and Northern blot analysis for Cdx1 and cyclin D1. Cdx1 protein was weakly detected at 12 h, but significantly elevated by 24 h, and modestly increased further by 48 h (Figure 3b ). Cyclin D1 protein levels fell dramatically between 24 and 48 h in the Adeno-Cdx1-treated cells. At 12 and 24 h, cyclin D1 protein levels were only minimally diminished and comparable to those of Adeno-Null-treated cells at 48 h. A similar pattern was noted in cyclin D1 mRNA levels. Normalized cyclin D1 mRNA levels were reduced to 40% of control levels by 48 h, with the greatest reduction occurring between 24 and 48 h (Figure 3b) . A small reduction of 10 and 20% in cyclin D1 mRNA levels was noted at 12 and 24 h, respectively (Figure 3b ). This compares with the 20% reduction observed in the Adeno-Null-treated cells at 48 h (Figures 2d and 3b) . Taken together, these observations suggest that the Figure 3 Time course analysis of cell-cycle arrest and reductions in cyclin D1 mRNA and protein levels. (a) DLD1 cells were cultured and treated as before, except that they were fixed and stained with propidium iodide at the indicated time points. DNA content was determined by flow cytometry. Data from three separate experiments were compiled (n ¼ 6). Assignment to G0/G1, S, or G2/M was made as before. The %G0/G1 for each treatment was averaged, and the mean and standard deviation for each is reported graphically. Black bar: control uninfected; grey bar: Adeno-Null treated; white bar: Adeno-Cdx1 treated. (b) Whole-cell extracts and total RNA were isolated from Adeno-Cdx1-treated cells at 12, 24, and 48 h postinfection, as well as control uninfected (at 48 h) and Adeno-Null-infected cells (48 h). A Western blot analysis for cyclin D1 was performed on 50 mg of extract. The blot was stripped and reprobed for loading control a-actin, as well as Cdx1. A Northern blot analysis for cyclin D1 mRNA levels was also carried out on 10 mg of total RNA. The blot was sequentially probed for cyclin D1 and the loading control ribosomal phosphoprotein 36B4. The figure is a composite made from a single experiment. Control: control uninfected cells; Adeno-Null: Adeno-Null infected cells; Adeno-Cdx1: Adeno-Cdx1-treated cells Cdx1 inhibits proliferation by reducing cyclin D1 expression J Lynch et al G0/G1 arrest and reductions in cyclin D1 mRNA and protein occur concurrently and are preceeded by the induction of Cdx1 expression.
Cdx1 expression reduces G1/S cyclin-dependent kinase activity
The G1 cdk kinase activity appears diminished based on the pRb western. This could be due to reduced cdk protein levels or inhibited kinase activity. Western immunoblotting and in vitro kinase assays were performed to differentiate between these possibilities. Cdk4, cdk6, and cdk2 levels and activity were measured on the same extracts prepared from sham-infected, Adeno-null-infected, or Adeno-Cdx1-treated DLD1 cells. Cdk4 protein levels were modestly reduced by Cdx1 (Figure 4a ). Additionally, Cdk4-associated activity was weak; however, we did observe a 40-50% reduction in cdk4 kinase activity with Cdx1 expression (Figure 4a , c). This reduced activity may derive from both reduced cdk4 protein and reduced cyclin D1 levels. Cdk6 kinase activity was considerably greater than that associated with cdk4. We observed a more substantial 60-75% reduction in cdk6 kinase activity with Cdx1 expression Moreover, there was no change noted in cdk6 protein levels (Figure 4b, c) . This suggests that the reduction was likely due to diminished cyclin D1 expression alone. By contrast, Adeno-Null treatment only slightly reduced cdk6 kinase activity by an average of 20%. Cdx1 expression reduced cdk 2 kinase activity by 70% ( Figure 5 ). This reduction was not due to loss of cdk2 protein (Figure 5 ), but more likely due to diminished cyclin A and cyclin B levels as well as some redistribution of low levels of cdk inhibitors (p21, p27, or p57) from cyclin D1-cdk4/6 complexes to cdk2 (Sherr, 2000) .
Cyclin D1 expression 'rescues' Cdx1 G0/G1 arrest
The data indicate that diminished cyclin D1 levels may be the primary mechanism by which Cdx1 inhibits the proliferation of DLD1 cells. If this is the case, restoration of cyclin D1 expression should reverse Cdx1-mediated inhibition of proliferation. We tested this hypothesis by coinfecting cells with Adeno-Cdx1 and an adenovirus containing a human cyclin D1 cDNA (Ad-cyclin D1). A small amount of the Ad-cyclin D1 virus was sufficient to reverse the G0/G1 accumulation Figure 4 Cdx1 expression reduces cdk4/cdk6-associated pRb kinase activity in DLD1 cells. (a) DLD1 cells were cultured and treated as before, and IP-extracts isolated at 48 h. Duplicate 100 mg samples of each extract were subject to IP with an antibody for cdk4 or with a control rabbit IgG. The cdk4-associated kinase activity present in the IP products was assayed. An immunoblot for cdk4 and a-actin was performed to confirm cdk4 protein levels. Con: control uninfected cells; Null: Adeno-null-infected cells; Cdx1: Adeno-Cdx1-treated cells. (b) Similar study as in (a) except duplicate samples of each extract were subject to IP with an antibody specific for cdk6 or with a control rabbit IgG. (c) The 32 Plabeled products were quantified by a phosphoimager. The 32 P incorporation values were normalized across three experiments and then averaged and a standard deviation calculated (n ¼ 6). Black bars: Cdk 4 kinase activity. White bars: Cdk6 kinase activity Figure 5 Cdx1 expression reduces cdk2-associated pRb kinase activity in DLD1 cells. (a) The DLD1 IP-extracts were examined for cdk2-associated kinase activity using purified histone H1 as substrate. An immunoblot for cdk2 and a-actin was performed to confirm equal levels. A representative of three experiments is presented. (b) The 32 P-labeled products were quantified and normalized as before, and the average and a standard deviation calculated (n ¼ 6) Cdx1 inhibits proliferation by reducing cyclin D1 expression J Lynch et al induced by Cdx1 at 48 h ( Figure 6 ). Most significantly, cyclin D1 coexpression also reversed the induction of hypophosphorylated pRb (Figure 6 ). Adeno-Null modestly reduced the Cdx1-mediated G0/G1 accumulation, but did not affect pRb phosphorylation levels ( Figure 6 ). Therefore, cyclin D1 expression is sufficient to abrogate Cdx1's antiproliferative effects.
The Cdx1 G0/G1 arrest is a specific activity of the Cdx1 protein
To address the issue of the specificity of Cdx1's antiproliferative effects, we tested truncated Cdx1 constructs. We generated Cdx1 clones in which the Nterminus (Cdx1 141À268 ) or the C-terminus (Cdx1 Cdx1 1À223 ) was deleted (Figure 7a) . These constructs were then subcloned into an expression vector and tested for activity (Figure 7b, c) . Transient transfection of these four expression vectors (pRC/CMV, the wildtype pRC/CMV-Cdx1-Wt, and the truncations pRC/ CMV-Cdx1-ND and pRC/CMV-Cdx1-CD) demonstrated high levels of Cdx1-Wt and Cdx1-ND protein expression ( Figure 7b ). As DLD1 cells transfect poorly using most techniques, we used HCT116 cells to test the vectors. The Cdx1-CD protein was not detected because the epitope recognized by the polyclonal antibody was in the deleted C-terminus. However, the Cdx1-CD expression vector was nearly as strong as the Cdx1-Wt protein in transactivation of the Cdx-responsive sucraseisomaltase promoter (Figure 7c) . The Cdx1-ND vector was unable to activate this reporter, as was expected given that the N-terminus contains a transcriptionactivating domain . Alternatively, the Cdx1-ND vector was able to act as a dominantnegative inhibitor of endogenous CDX2 transcriptional activity in DLD1 cells (data not shown).
These constructs were then tested for their ability to induce antiproliferative effects in colon cancer cells. As transient transfection methods will be significantly less efficient at expressing Cdx1 than the adenoviral method, we needed to identify and enrich for transfected cells in our study population. We first utilized the MACSelect Transfected Cell Selection Kit, however, only the HCT116 cells would express the truncated MHC H2k k marker used in the selection. HCT116 cells were transiently transfected with each of the constructs, along with pMACS k k .II (Miltenyi), the marker for transfection. After 48 h, an enriched population of transfected cells was isolated using the MACSelect system. These cells were fixed and stained for propidium iodide, and flow cytometry was utilized to quantify the DNA content in the enriched pool. Cdx1-Wt expression led to a small but statistically significant increase in the accumulation of cells in G0/G1 when compared with the empty vector control and Cdx1-ND mutant (data not shown). The Cdx1-CD mutant differed only from the Cdx1-ND construct. Neither were significantly different from the control transfection. Therefore, only Cdx1-wt could elicit an accumulation of HCT116 cells in G0/G1.
We utilized electroporation as an alternate approach to study the truncation constructs in DLD1 cells. Cotransfection of a farnesylated-GFP expression construct could serve as both a marker of and control for transfection, and then DNA content could be measured in the GFP þ cells by flow cytometry. Additionally, we used electroporation to transfect transiently DLD1 cells, as this was the only method yielding transfection efficiencies high enough for the flow-cytometry method. DLD1 electroporation efficiencies ranged between 30 and 70%. At 48 h, the cells were fixed and stained with propidium iodide. Flow cytometry was used to quantify DNA content in GFP þ cells. Cdx1-wt and Cdx1-CD were equally effective at inducing a G0/G1 accumulation of cells (Figure 8 ). On average, there was a 1.7-fold increase in the number of cells in the G0/G1 phase. This induction equaled that observed by the adeno-Cdx1 construct in earlier experiments (Table 1 ). The Cdx1-ND construct behaved indistinguishably from the empty control pRC/CMV construct with respect to G0/G1 accumulation (Figure 8 ). In summary, the N-terminus but not the C-terminus of Cdx1 is required to inhibit proliferation in HCT116 and DLD1 cells. This indicates that the inhibition of proliferation is a specific effect of Cdx1 and correlates with the ability of the protein to function as a transcription factor. Furthermore, the absence of a pro-proliferative effect by the dominantnegative Cdx1-ND construct in DLD1 cells that indicates that the endogenously expressed CDX2 protein had no significant antiproliferative effect on its own.
Cdx1 reduces cyclin D1 gene expression
To determine if Cdx1 reduces cyclin mRNA levels by increasing its rate of destruction, we carried out mRNA stability studies using the RNA polymerase inhibitor, Actinomycin D. We observed a gradual decay of cyclin A, B, and D1 mRNAs over the 24 h period (data not shown). Cdx1 expression did not appear to alter the rate of mRNA decay. The mRNA present from these three cyclins were quantified, and the values, expressed as percentage of T 0 RNA levels, were plotted against time. Cyclins A, B, and D1 mRNA decay rates were not significantly altered by Cdx1 expression (Figure 9a ). To confirm that the Actinomycin D treatment was fully inhibited RNA polymerase activity, we examined c-Myc mRNA levels by Northern blot. c-Myc mRNA expression was undetectable by 4 h of Actinomycin D treatment (data not shown). Of note, c-Myc mRNA levels were diminished by Cdx1 expression 3-4-fold when compared with adeno-Null controls (data not shown). A full-length human cyclin D1 promoter-luciferase reporter construct was assayed in the presence of Cdx1-Wt or the Cdx1-ND mutant. We observed a modest 30% reduction of cyclin D1 promoter activity in the fulllength hD1(-1749) promoter with Cdx1-Wt expression (Figure 9b ). This reduction is observed despite the induction of the basal vector (pA3-Luciferase) over four-fold by Cdx1-Wt. A greater reduction of cyclin D1 promoter activity by Cdx1 might therefore be masked by this nonspecific vector induction. In summary, Cdx1 expression does not significantly alter cyclins A, B, and D1 mRNA decay rates, but does reduce cyclin D1 promoter activity in DLD1 cells.
Discussion
The continuous renewal of the intestinal epithelium is a highly ordered and regulated process. This process becomes increasingly disordered in the progression to adenomas and carcinomas in the human colon. The data presented here establish in a robust fashion that restoration of Cdx1 expression in human colon cancer cells leads to inhibition of proliferation by a mechanism that involves reduction of cyclin D1 gene expression, with associated reduction in G1 Cdk kinase activity.
We used a variety of independent techniques to express Cdx1 transiently in human colon cancer cells. In a prior study, we used both transient and stableinducible techniques to express Cdx1 in nontransformed cells. In each case, we observed that Cdx1 expression led Immunoblot for Cdx1 and Cdx1-N-terminus truncated proteins after transient transfection. At 48 h, whole-cell protein extracts were prepared subjected to PAGE and immunoblot using a polyclonal antibody (CPSP) recognizing an epitope on Cdx1's C-terminus. (c) Transcriptional activity of the mutant and full-length Cdx1 constructs, cotransfected with a Cdx responsive reporter, the SI (À183 to þ 54) luciferase, and transfection control (pRL-CMV) in HCT116 cells. Luciferase activity was measured at 48 h and normalized to total protein and renilla luciferase levels Cdx1 inhibits proliferation by reducing cyclin D1 expression J Lynch et al to reduced proliferation that was not associated with increased apoptotic cell death. Experiments with Cdx1 truncation mutants establish that this is a specific effect of the Cdx1 transcription factor. Furthermore, these antiproliferative effects likely require Cdx1 transcriptional activity, as it was the transcriptionally inactive Cdx1-ND mutant that lost the ability to induce the G0/ G1 arrest. Lastly, and perhaps most importantly, we have been able to demonstrate in several divergent cell lines a conserved mechanism by which Cdx1 induces cell-cycle withdrawal. In both studies, Cdx1 expression lead to a G0/G1 accumulation and reduced pRb and p130 protein phosphorylation. This was due to reduced cyclin D1 gene expression, which thereby diminished G1 cdk kinase activity. These findings are consistent with current models of intestinal epithelial development. Control of proliferation, differentiation, and lineage determination are not well understood, but are known to depend upon the actions of several signaling pathways and transcription factors, including Notch, Hedgehog, Wingless (Wnt), Hes1, Math1, NeuroD, Forkhead-6, KLF-4, KLF-5, HNF-1, GATA 4, and the Caudal-related genes (Cdx1 and Cdx2) (Kaestner et al., 1997; Freund et al., 1998; Korinek et al., 1998; Mutoh et al., 1998; Beck et al., 2000; Jensen et al., 2000; Clatworthy and Subramanian, 2001; Dang et al., 2001; Fang et al., 2001; Sun et al., 2001; Yang et al., 2001; Boudreau et al., 2002) . Many of these signaling pathways and transcription factors are recognized to regulate both differentiation and proliferation (Korinek et al., 1998; Mutoh et al., 1998 Mariadason et al., 2001; Naishiro et al., 2001; van de Wetering et al., 2002) . In general, factors that promote differentiation also reduce proliferation. Given that Cdx1 and Cdx2 have been implicated in promoting enterocyte and colonocyte differentiation, they might be expected to inhibit proliferation as well. Our observations support this hypothesis. Our findings may help resolve conflicting reports. It has been hypothesized that Cdx1 promotes intestinal epithelial proliferation, because Cdx1 is expressed highly in the crypt compartment and because Cdx1's expression is induced by oncogenic Wnt/b-catenin and Ras signaling (Lorentz et al., 1999; Lickert et al., 2000; Soubeyran et al., 2001) . However, known proliferationand tumor-suppressors like Cdx2 and p16 are expressed in crypt cells (Dai et al., 2000; Rings et al., 2001) . Furthermore, Cdx1 is expressed at low but detectable levels in the nonproliferating surface and villous epithelial cells as well . Moreover, Cdx1 expression is generally diminished or actively silenced in human colon cancers Suh et al., 2002) despite the near-universal activation of Wnt/b-catenin and Ras signaling pathways in human colorectal carcinomas. This last finding is inconsistent with Cdx1 acting to promote the oncogenic Wnt/b-catenin and Ras signaling pathways. We would expect Cdx1 levels to be increased if this were the case.
Lastly, Cdx1 has been described to be an oncogene due to its presence in human metaplasias of the esophagus and stomach (Soubeyran et al., 2001) , its reported ability to induce soft-agar growth in 3T3 and IEC6 cells (Maulbecker and Gruss, 1993; Soubeyran et al., 1999) , induce PCNA expression and BrdU incorporation (Oh et al., 2002) , as well as promote proliferation in IEC6 and CaCo2 cells (Lorentz et al., 1997; Soubeyran et al., 1999) . However, the expression of Cdx1 in intestinal metaplastia is not evidence for a proliferative function but rather an association with an intestinal cell phenotype; Cdx2 and sucrase isomaltase have also been associated with intestinal metaplasia (Bai et al., 2002) . Additionally, the expression of both Cdx1 and Cdx2 decreases or is lost during the transition from intestinal metaplasia to dysplasia to cancer Bai et al., 2002) , further supporting a role in constraining rather than augmenting proliferation. Finally, in contrast to the above reports, we found Cdx1 expression reduced rather than increased proliferation of cells in culture, and a stable-inducible Cdx1 expression vector could not induce 3T3 cell soft-agar growth.
In considering why our observations differ from other reports, several possibilities emerge, including that the IEC6 and 3T3 cells in our study could correspond to different subclones, or that murine Cdx1 (used in our study) and human CDX1 (used in other studies) possess different biological properties. Both possibilities are unlikely. In particular, murine and human Cdx1 proteins are highly conserved, with nearly 85% conserved amino-acid identity. Rather, it is more plausible that different techniques are responsible for the observed differences. Classically, the study of antiproliferative agents has been carried out with stable-inducible expression constructs or transient expression methods including adenoviruses and transfection (Polyak et al., 1997; Somasundaram et al., 1997; van de Wetering et al., 2002) . Stable-inducible or transient expression of Cdx1 is by design more sensitive for the detection of antiproliferative effects than the methods utilized in the other reports-namely, stable transfection with a constitutive CDX1 expression vector and pooling transfected cells rather than isolating individual clones (Lorentz et al., 1997; Soubeyran et al., 1999 Soubeyran et al., , 2001 . One potential criticism of our study is that we cannot be certain that expression of Cdx1 leads to the induction of genes that are in vivo transactivated by Cdx2. However, the hypothesis that there are Cdx1-and Cdx2-specific targets may be an artefact of early studies that suggested Cdx1 and Cdx2 had distinctive, nonoverlapping patterns of intestinal expression. It is increasingly apparent that the Cdx1 and Cdx2 have complementary and overlapping roles in development (van den Akker et al., 2002) . This is understandable given their structural homology, common DNA sequence requirements, and overlapping distributions of expression.
It is interesting to speculate how the cell-cycle inhibitory property of Cdx1 may function normally in intestinal crypt cells as well as in neoplasia. Cdx1 (and Cdx2) may serve as a feedback mechanism to constrain the proliferation of the rapidly dividing crypt epithelial cells, while at the same time promoting their differentiation. In intestina neoplasia, Cdx1 may be preferentially targeted for silencing because of its effects upon cyclin D1 levels and activity. Cyclin D1/cdk kinase activity is known to be critically important for the proliferation of neoplastic cells in the presence of wild-type pRb (Donnellan and Chetty, 1998) and its expression is typically upregulated in a number of human cancers including colon cancer (Donnellan and Chetty, 1998) . In colon carcinogenesis, this is an early event and is most commonly caused by increased transcriptional activity due to markedly enhanced Wnt/b-catenin-and Rassignaling, rather than gene duplications (Albanese et al., 1995; Arber et al., 1996; Shtutman et al., 1999; Tetsu and McCormick, 1999) . It therefore stands to reason that the neoplastic cells that inactivate Cdx1 and enhance cyclin D1 gene expression would obtain a proliferative advantage.
In summary, the expression of Cdx1 in human colon cancer DLD1 cells reduces proliferation by diminishing cyclin D1 gene expression. This results in decreased G1 cyclin D1-cdk4/6 kinase activity and hypophosphorylated pRb and p130 proteins. This is a specific effect likely requiring Cdx1 transcriptional activity, as it requires an intact Cdx1 N-terminus but not the Cterminus. This mechanism may regulate the swift transition from rapidly proliferating crypt cells to nondividing, mature enterocytes in the intestinal and colonic crypts. It may also function to reduce the proliferation of neoplastic cells and thereby retard tumor formation in the colon.
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